Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.cct.2009.04.006
DC FieldValue
dc.titleAn assessment of the understanding and motivations of patients with schizophrenia about participating in a clinical trial
dc.contributor.authorChong, S.-A.
dc.contributor.authorOng, Y.Y.
dc.contributor.authorSubramaniam, M.
dc.contributor.authorAbdin, E.
dc.contributor.authorMarx, C.E.
dc.contributor.authorCampbell, A.V.
dc.date.accessioned2011-10-06T03:10:30Z
dc.date.available2011-10-06T03:10:30Z
dc.date.issued2009
dc.identifier.citationChong, S.-A., Ong, Y.Y., Subramaniam, M., Abdin, E., Marx, C.E., Campbell, A.V. (2009). An assessment of the understanding and motivations of patients with schizophrenia about participating in a clinical trial. Contemporary Clinical Trials 30 (5) : 446-450. ScholarBank@NUS Repository. https://doi.org/10.1016/j.cct.2009.04.006
dc.identifier.issn15517144
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/27533
dc.description.abstractEnrollment of an adequate number of subjects for a clinical trial is a perennial challenge and this might arguably be even more difficult and complex in trials involving patients with schizophrenia. In this paper, we used a modification of the Prospective Preference Approach (PPA) as a prelude to an actual randomized placebo-controlled trial of a cognitive-enhancing agent for patients with schizophrenia. This approach sought to test and enhance subjects' understanding of the key concepts of the trial, and administered the PPA at baseline and following a brief educational module. The motivations and concerns regarding potential participation in the proposed trial were also elicited by the PPA. Of one hundred ninety patients with schizophrenia recruited for this PPA study, only 12 (6.3%) were assessed to have understood all key trial-related concepts after the initial explanation and baseline PPA administration (prior to the educational module). Following the education module, however, there was significant increase in the number of patients who understood all key trial elements. Younger age and higher level of education were significant factors associated with better understanding of the proposed trial. The main reasons cited for wishing to participate in clinical trials were personal medical benefits and altruistic desire to help others. Concerns regarding the safety of the trial medication were expressed in over 80% of the subjects. PPA administration with educational module supplementation may provide a valuable addition to clinical trial procedures in patients with schizophrenia. © 2009 Elsevier Inc. All rights reserved.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1016/j.cct.2009.04.006
dc.sourceScopus
dc.subjectClinical trial
dc.subjectEducational intervention
dc.subjectEnrollment
dc.subjectMotivations
dc.subjectPlacebo
dc.subjectRandomization
dc.typeArticle
dc.contributor.departmentDEAN'S OFFICE (MEDICINE)
dc.description.doi10.1016/j.cct.2009.04.006
dc.description.sourcetitleContemporary Clinical Trials
dc.description.volume30
dc.description.issue5
dc.description.page446-450
dc.identifier.isiut000270073800012
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

5
checked on Jul 15, 2019

WEB OF SCIENCETM
Citations

5
checked on Jul 15, 2019

Page view(s)

222
checked on May 24, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.